Mizuho lowered the firm’s price target on ResMed (RMD) to $300 from $310 and keeps an Outperform rating on the shares following the fiscal Q1 report. The firm says GLP-1s are not presenting a headwind yet for ResMed while its US competition is stable.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: